Your search returned 39 studies. (Get alerts for new studies):
- Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malig Who Relapse/Progress After Rituximab
Conditions: Lymphocytic Leukemia - Mantle Cell Lymphoma
1 Location available
- Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
Conditions: Lymphoma
7 Locations available
- Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma
Conditions: Mantle Cell Lymphoma
1 Location available
- MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine
Conditions: Diffuse Large B-Cell Lymphoma - Transformed Follicular Lymphoma - Mantle Cell Lymphoma - Burkitt's Lymphoma
1 Location available
- EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
Conditions: Lymphoma, Mantle Cell
1 Location available
- Oral Clofarabine for Relapsed/Refractory Indolent B-cell NHL and Mantle Cell Lymphoma
Conditions: Follicular Lymphoma - Marginal Zone Lymphoma - Mantle Cell Lymphoma - Small Lymphocytic Lymphoma - Lymphoplasmacytic Lymphoma - Low Grade B-cell Lymphoma, Not Otherwise Specified
2 Locations available
- Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Conditions: Non-Hodgkin's Lymphoma (NHL)
9 Locations available
- Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Comb
Conditions: Contiguous Stage II Mantle Cell Lymphoma - Noncontiguous Stage II Mantle Cell Lymphoma - Stage I Mantle Cell Lymphoma - Stage III Mantle Cell Lymphoma - Stage IV Mantle Cell Lymphoma
1 Location available
- Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma
Conditions: Mantle Cell Lymphoma - Lymphoma
2 Locations available
- Phase I/II Study of B Cell Malignancies Using T Cells Expressing an Anti-CD19 Chimeric Receptor: Assessment of the Impact of Lymphocyte Depletion Prio
Conditions: Chronic Lymphocytic Leukemia - Small Lymphocytic Lymphoma - Mantle Cell Lymphoma - Follicular Lymphoma - Large Cell Lymphoma
1 Location available
- A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic
Conditions: Lymphoma, Mantle-Cell - Leukemia, Lymphocytic, Chronic, B-Cell - Leukemia, Hairy Cell - Waldenstrom Macroglobulinemia - Multiple Myeloma
1 Location available
- Ofatumumab and Bortezomib in Subjects With Relapsed CD20+ NHL
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma - Recurrent Grade 1 Follicular Lymphoma - Recurrent Grade 2 Follicular Lymphoma - Recurrent Grade 3 Follicular Lymphoma - Recurrent Mantle Cell Lymphoma
1 Location available
- Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Conditions: Acute Myeloid Leukemia - Myelodysplastic Syndrome - Chronic Lymphocytic Leukemia - Mantle Cell Lymphoma
1 Location available
- A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Conditions: CD27 Expressing B-cell Malignancies - CD27 Expressing Solid Tumors - Chronic Lymphocytic Leukemia - Burkett's Lymphoma - Mantle Cell Lymphoma - Primary Lymphoma of the Central Nervous System - Marginal Zone B Cell Lymphoma - Solid Tumor - Metastatic Melan
5 Locations available
- Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
Conditions: Multiple Myeloma - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma - Non Hodgkin's Lymphoma - Waldenstroms - Mantle Cell Lymphoma
1 Location available
- Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine
Conditions: Mantle Cell Lymphoma
9 Locations available
- AMG 319 Lymphoid Malignancy FIH
Conditions: Cancer - Chronic Lymphocytic Leukemia - Diffuse Large Cell Lymphoma - Hematologic Malignancies - Hematology - Leukemia - Low Grade Lymphoma - Lymphoma - Mantle Cell Lymphoma - Non-Hodgkin's Lymphoma - Oncology - Oncology Patients - T Cell Lymphoma - Tumor
2 Locations available
- Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma - Recurrent Adult Diffuse Mixed Cell Lymphoma - Recurrent Adult Diffuse Small Cleaved Cell Lymphoma - Recurrent Grade 3 Follicular Lymphoma - Recurrent Mantle Cell Lymphoma
1 Location available
- TLR8 Agonist VTX-2337 in Combo With Local Radiation in Low-Grade B-cell Lymphomas
Conditions: Lymphoma, Non-Hodgkin - Cutaneous Lymphoma - Large B Cell Diffuse Lymphoma - Mantle Cell Lymphoma - Marginal Zone B-Cell Lymphoma - Peripheral T-cell Lymphoma, Large Cell - Waldenstrom Macroglobulinemia
1 Location available
- Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant
Conditions: Mantle Cell Lymphoma
1 Location available
- Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Conditions: Mantle-Cell Lymphoma
1 Location available
- Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
Conditions: Lymphoma
1 Location available
- Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin'
Conditions: Non-Hodgkin's Lymphoma - Mantle Cell Lymphoma
27 Locations available
- Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
Conditions: Contiguous Stage II Mantle Cell Lymphoma - Noncontiguous Stage II Mantle Cell Lymphoma - Recurrent Mantle Cell Lymphoma - Stage I Mantle Cell Lymphoma - Stage III Mantle Cell Lymphoma - Stage IV Mantle Cell Lymphoma
1 Location available
- Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
Conditions: Lymphoma, Mantle-Cell
1 Location available
- Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
Conditions: Mantle Cell Lymphoma
2 Locations available
- A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bor
Conditions: Mantle Cell Lymphoma
26 Locations available
- Pilot Study for Patients With Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma
Conditions: Acute Lymphocytic Leukemia - Follicular Lymphoma - Chronic Lymphocytic Leukemia (CLL) - Mantle Cell Lymphoma - Prolymphocytic Leukemia - Large Cell Lymphoma
1 Location available
- A Phase 1-2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia (CLL) - Diffuse Large B-Cell Lymphoma (DLBCL) - Non-Hodgkin's Lymphoma (NHL) - Follicular Lymphoma (FL) - Mantle Cell Lymphoma (MCL)
1 Location available
- Tandem Auto-Allo Transplant for Lymphoma
Conditions: Diffuse, Large B-Cell, Lymphoma - Lymphoma, Low-Grade - T-Cell Lymphoma - Mantle-Cell Lymphoma - Hodgkin's Lymphoma - Chronic Lymphocytic Leukemia - Lymphoma, Small Lymphocytic
2 Locations available
- Imexon for Relapsed Follicular and Aggressive Lymphomas
Conditions: Follicular Lymphoma - Diffuse Large B Cell Lymphoma - Mantle Cell Lymphoma - Burkitt's Lymphoma
1 Location available
- Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Conditions: Lymphoma
41 Locations available
- Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Relapsed B-Cell Non-Hodgkin Lym
Conditions: Leukemia - Lymphoma
1 Location available
- Study of Bortezomib in Combination With Cyclophosphamide and Rituximab
Conditions: Mantle Cell Lymphoma - Lymphoma
1 Location available
- Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodg
Conditions: Indolent Non-Hodgkin's Lymphoma - Chronic Lymphocytic Leukemia - Mantle Cell Lymphoma
11 Locations available
- Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukem
Conditions: Indolent Non-Hodgkin Lymphoma - Mantle Cell Lymphoma - Chronic Lymphocytic Leukemia
3 Locations available
- Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma
Conditions: Mantle Cell Lymphoma
1 Location available
- Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)
Conditions: Mantle Cell Lymphoma
1 Location available
- CD 19-Specific Donor T Cells for B Cell Malignancies After Allogeneic Transplant
Conditions: Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia - Recurrent Adult Acute Lymphoblastic Leukemia - Recurrent Adult Diffuse Large Cell Lymphoma - Recurrent Adult Immunoblastic Large Cell Lymphoma - Recurrent Mantle Cell Lymphoma
1 Location available
|